Table 2.

IC₅₀ values of IBL-202 and venetoclax

	IC50		P*
	Alone	In combination
Primary CLL cells + CD40L fibroblasts
IBL-202	0.47 ± 0.32 µM	0.24 ± 0.03 µM	.01
Venetoclax	30.2 ± 25.4 nM	2.40 ± 0.30 nM	<.01
Primary CLL cells + HS-5 fibroblasts
IBL-202	0.94 ± 0.24 µM	0.53 ± 0.18 µM	<.01
Venetoclax	36.37 ± 8.34 nM	5.30 ± 1.80 nM	<.01
OSU-CLL cells
IBL-202	0.61 ± 0.05 µM	0.07 ± 0.01 µM	.01
Venetoclax	295 ± 108 nM	14.3 ± 1.20 nM	<.01
OSU-CLL-TP53ko cells
IBL-202	1.89 ± 0.16 μM	0.06 ± 0.01 µM	<.01
Venetoclax	18.5 ± 2.26 μM	0.63 ± 0.10 µM	.01

IC₅₀ values for IBL-202 and venetoclax, alone and in combination, against primary CLL cells and OSU-CLL cell lines were calculated from the dose-response analyses.

^*P values shown indicate that in each of the culture conditions and in the 2 OSU-CLL lines, combining the drugs resulted in a significant decrease in the IC₅₀ value for each drug compared with the IC₅₀ values for the drugs as single agents. P values were calculated using the t test function of GraphPad Prism software.